At BTG we are focused on bringing to market innovative products in specialist areas of medicine to better serve doctors and patients. Our growing portfolio of Interventional Medicine products is designed to advance the treatment of liver tumours, advanced emphysema, severe blood clots, and varicose veins, while our Specialty Pharmaceuticals portfolio offers antidotes that alleviate toxicity and treat rare conditions. Healthcare is constantly evolving – so BTG never stands still. Inspired by a deep understanding of our customers’ needs, we’re working to meaningfully improve the lives of patients and their healthcare experience. Our competitive advantage is our dedication to finding smart, often unconventional solutions to complex medical problems. Many of our products combine medicines, device technology and new techniques in order to deliver more targeted treatments. We also invest in the clinical evidence that helps demonstrate the value of our products to doctors, patients, and healthcare systems. Doing what’s right for patients is what gets us to work in the morning. It’s part of our DNA. By staying true to this principle and our values, we’ve earned a strong reputation for the quality of our products and our commitment to innovation. Whether developed in our own labs or in partnership with clinicians, academics, and other companies, we believe passionately that medical innovation has the power to improve human health. Imagine where we can go.
Show more
London, GB
Size (employees)
1,355 (est)
BTG was founded in 1948 and is headquartered in London, GB
Report incorrect company information

BTG Office Locations

BTG has offices in Hong Kong, London, Alzenau, Conshohocken and in 4 other locations
London, GB (HQ)
5 Fleet Pl
Rosedale, AU
RSD Turretfield RC, 129 Holland Road
Ottawa, CA
200 11 Hines Rd
Alzenau, DE
19 Industriestraße
Hong Kong, HK
Room 2905, 29/Floor, ACE Tower, Windsor House, 311 Gloucester Road Causeway Bay Hong Kong
Neihu District, TW
4D, No. 66, Sec. 1, Neihu Road Neihu District Taipei City Taiwan
Show all (8)
Report incorrect company information

BTG Financials and Metrics

BTG Financials

BTG's revenue was reported to be £570.50 m in FY, 2017

Revenue (FY, 2017)

570.5 m

Gross profit (FY, 2017)

390.6 m

Gross profit margin (FY, 2017), %


Net income (FY, 2017)

33.6 m

EBITDA (FY, 2017)

110.8 m

EBIT (FY, 2017)

57.5 m

Market capitalization (31-Oct-2017)

2.9 b

Closing share price (31-Oct-2017)


Cash (31-Mar-2017)

155.5 m
BTG's current market capitalization is £2.9 b.
GBPFY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017


75 m84.8 m98.5 m111.4 m197 m233.7 m290.5 m367.8 m447.5 m570.5 m

Revenue growth, %


Cost of goods sold

32.1 m37.1 m32.8 m34.1 m56.3 m67.2 m95 m114.7 m140.8 m179.9 m

Gross profit

42.9 m47.7 m65.7 m77.3 m140.7 m166.5 m195.5 m253.1 m306.7 m390.6 m
GBPFY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

8.8 m(13.1 m)11.3 m9.2 m14.6 m16.4 m24.3 m33.6 m60.5 m33.6 m

Cash From Operating Activities

13.4 m(1.8 m)5.8 m(12 m)47.2 m55.5 m48.5 m47.5 m95.6 m74.2 m

Cash From Financing Activities

(100 k)1.4 m(600 k)200 k200 k102.7 m146.2 m(19.7 m)

Net Change in Cash

14.2 m19.9 m4.6 m(18.1 m)43.1 m51.2 m(118.2 m)34.8 m65.7 m9.2 m
GBPY, 2017


449.7 k

Financial Leverage

1.3 x
Show all financial metrics
Report incorrect company information

BTG News and Updates

Antivenom Global Market Top Key Players – CSL Behring , Merck & Co., Inc. , BTG Plc , Pfizer , Haffkine Bio-Pharmaceutical Corporation and Forecast to 2022

Wiseguyreports.Com Added New Market Research Report On -“Antivenom Market 2018 Manufacturers, Applications and Future Demand Forecast to 2022”. Posted via Industry Today. Follow us on Twitter @IndustryToday

Tumor Ablation Market Projected to Discern Stable Expansion at 12.2% CAGR During 2016-2024

Transparency Market Research has announced the addition of the “Tumor Ablation Market: Global Industry Analysis and Opportunity Assessment, 2016-2024"report to their offering. Posted via Industry Today. Follow us on Twitter @IndustryToday

ABRY Partners buys majority stake in BTG

ABRY Partners has acquired a majority stake in Breakthrough Technology Group, a private cloud service provider focused on supporting enterprise workloads and IT services. No financial terms were disclosed.

Bitcoin Gold mining to commence following imminent hard fork

The small team instigating this new bitcoin fork are aiming to make digital currency available to more people. The post Bitcoin Gold mining to commence following imminent hard fork appeared first on Computer Business Review.

Launch of New, Narrative-Based Men’s Fashion Site:

PRESS RELEASE:, a premier e-commerce destination for the global, eclectic tastemaker, today launched a revolutionary men's fashion site focused on telling the stories of and sourcing the next generation of designers and cultural ...
Report incorrect company information